The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time. The Company is taking precautionary measures in response to the evolving coronavirus (COVID-19) situation in the Seattle area.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...
Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has made two orphan drug designations for ALPN-101, Alpine’s first-in-class selective dual T cell costimulation inhibitor, for the prevention and for the treatment of acute GVHD.
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
Anyone researching Alpine Immune Sciences, Inc. (NASDAQ:ALPN) might want to consider the historical volatility of the...
Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) just released its quarterly report and things are looking bullish. Sales...
Every investor in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) should be aware of the most powerful shareholder groups...